Jun-Ichi Kouyama
Overview
Explore the profile of Jun-Ichi Kouyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamada S, Uchida Y, Kouyama J, Naiki K, Yamaguchi H, Nakayama N, et al.
Clin J Gastroenterol
. 2024 Dec;
18(1):145-153.
PMID: 39625631
A 75-year-old Japanese woman experienced persistent fatigue and progressive jaundice for 6 weeks, and was subsequently diagnosed with acute liver failure. She had not received any immunosuppressive therapies and/or antineoplastic...
2.
Soma N, Uchida Y, Kouyama J, Naiki K, Usui N, Sato A, et al.
J Gastroenterol
. 2024 Oct;
60(1):96-106.
PMID: 39412575
Background: Covert hepatic encephalopathy (CHE) significantly impacts the quality of life and prognosis in patients with liver cirrhosis. This study aims to analyze the prevalence and risk factors of CHE...
3.
Yamada S, Uchida Y, Kouyama J, Naiki K, Tsuji S, Uemura H, et al.
Hepatol Res
. 2024 Mar;
54(10):877-887.
PMID: 38517681
Aim: Patients with chronic hepatitis B virus (HBV) infection experiencing viral breakthrough (BTH) or partial response (PR) during lamivudine (LAM) or entecavir hydrate (ETV) administration often took ETV plus tenofovir...
4.
Uchida Y, Imai Y, Tsuji S, Uemura H, Kouyama J, Naiki K, et al.
Hepatol Res
. 2023 May;
53(9):815-828.
PMID: 37243512
Aim: To determine the outcomes concerning portal venous blood flow and portosystemic shunts in patients with decompensated cirrhosis due to hepatitis C virus (HCV) infection who achieved sustained viral response...
5.
Uchida Y, Nakao M, Yamada S, Tsuji S, Uemura H, Kouyama J, et al.
PLoS One
. 2022 Feb;
17(2):e0262764.
PMID: 35180213
Background: To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in patients with chronic HBV infection. Methods:...
6.
Uchida Y, Uemura H, Tsuji S, Yamada S, Kouyama J, Naiki K, et al.
Hepatol Res
. 2022 Feb;
52(5):449-461.
PMID: 35113468
Background: The Japanese guidelines for the treatment of cirrhosis suggest zinc supplementation to prevent hepatic encephalopathy in patients with cirrhosis and zinc deficiency, although the factors that are associated with...
7.
Uchida Y, Inao M, Tsuji S, Uemura H, Kouyama J, Naiki K, et al.
Hepatol Res
. 2020 Sep;
50(12):1355-1364.
PMID: 32886950
Aim: To optimize the therapeutic strategy for patients with decompensated cirrhosis manifesting hepatic ascites and/or edema, factors affecting the outcome of patients receiving tolvaptan were evaluated. Methods: The subjects were...
8.
Uchida Y, Tsuji S, Uemura H, Kouyama J, Naiki K, Sugawara K, et al.
Hepatol Res
. 2020 Aug;
50(11):1264-1274.
PMID: 32833292
Aim: To optimize the therapeutic strategy for cirrhotic patients manifesting hepatic encephalopathy, factors affecting the outcome of patients receiving rifaximin were evaluated. Methods: The subjects were 95 patients receiving rifaximin....
9.
Uchida Y, Nakao M, Tsuji S, Uemura H, Kouyama J, Naiki K, et al.
J Med Virol
. 2020 Jul;
92(8):1370.
PMID: 32677098
No abstract available.
10.
Tsuji S, Uchida Y, Uemura H, Kouyama J, Naiki K, Nakao M, et al.
Hepatol Res
. 2019 Dec;
50(4):512-523.
PMID: 31837277
Aim: Factors responsible for impaired improvement of liver function despite sustained viral response after direct-acting antiviral agents therapies in cirrhotic patients with hepatitis C virus need to be elucidated. Methods:...